Patterns of use of sildenafil among commercially insured adults in the United States: 1998-2002
- PMID: 14973524
- DOI: 10.1038/sj.ijir.3901191
Patterns of use of sildenafil among commercially insured adults in the United States: 1998-2002
Abstract
Sildenafil is increasingly being marketed to younger healthcare consumers. The purpose of this study was to profile sildenafil use in commercially insured, adult beneficiaries. Annual ambulatory prescription claims data from 1998 to 2002, for a nationwide, random sample of over 5 million life-years of commercially insured adults (aged > or =18 y), were examined retrospectively. The overall prevalence of sildenafil use increased from 0.8% (1998) to 1.4% (2002), an 84% increase. While the growth in use slowed in older males, use became more pronounced in younger males and females and decreased in older females. The fastest growing segment of users was found to be males aged 18-45 y. The proportion of users who had two or more claims for a medication that is suspected of inducing erectile dysfunction (ED) and/or a marker for a suspected ED-inducing disease decreased over the study period. Our findings suggest that use may increase among younger male and female patients and those without an underlying etiologic reason for use.
Similar articles
-
Use of medications for erectile dysfunction in the United States, 1996 through 2001.J Urol. 2003 Mar;169(3):1040-2. doi: 10.1097/01.ju.0000045707.96565.cd. J Urol. 2003. PMID: 12576841
-
Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users.Int J Impot Res. 2002 Aug;14(4):259-65. doi: 10.1038/sj.ijir.3900883. Int J Impot Res. 2002. PMID: 12152115
-
Increasing incidence and importance of HIV/AIDS and gonorrhea among men aged >/= 50 years in the US in the era of erectile dysfunction therapy.Scand J Urol Nephrol. 2004;38(3):247-52. doi: 10.1080/00365590410025488. Scand J Urol Nephrol. 2004. PMID: 15204381
-
Past, present, and future: a 7-year update of Viagra (sildenafil citrate).Int J Clin Pract. 2005 Jun;59(6):680-91. doi: 10.1111/j.1368-5031.2005.00578.x. Int J Clin Pract. 2005. PMID: 15924597 Review.
-
[Safety of Sildenafil in men with cardiovascular diseases].Zhonghua Nan Ke Xue. 2005 Mar;11(3):223-5. Zhonghua Nan Ke Xue. 2005. PMID: 15804120 Review. Chinese.
Cited by
-
Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Mar 2;3(3):e201423. doi: 10.1001/jamanetworkopen.2020.1423. JAMA Netw Open. 2020. PMID: 32196105 Free PMC article.
-
Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data.Ann Intern Med. 2010 Jul 6;153(1):1-7. doi: 10.7326/0003-4819-153-1-201007060-00003. Ann Intern Med. 2010. PMID: 20621899 Free PMC article.
-
Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden.Eur J Clin Pharmacol. 2018 Feb;74(2):209-218. doi: 10.1007/s00228-017-2361-9. Epub 2017 Nov 3. Eur J Clin Pharmacol. 2018. PMID: 29101427 Free PMC article.
-
The Weekend Drug; Recreational Use of Sildenafil Citrate and Concomitant Factors: A Cross-Sectional Study.Front Med (Lausanne). 2021 Aug 20;8:665247. doi: 10.3389/fmed.2021.665247. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34490285 Free PMC article.
-
Sildenafil and suicide in Sweden.Eur J Epidemiol. 2021 May;36(5):531-537. doi: 10.1007/s10654-021-00738-4. Epub 2021 Apr 1. Eur J Epidemiol. 2021. PMID: 33796979 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical